Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations.

VARANI A; ASO E; LIRANE MACHADO MOUTINHO; BALERIO G; MALDONADO R

PSYCHOPHARMACOLOGY

SPRINGER

Lugar: Berlin; Año: 2014

0033-3158

Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations. Varani AP1, Aso E, Moutinho LM, Maldonado R, Balerio GN. Author information Abstract RATIONALE: Nicotine is a major active ingredient in tobacco and plays a major role in tobacco addiction. In rodents, repeated nicotine administration produces behavioral responses related to its addictive properties, such as reinforcing effects and physical dependence. OBJECTIVES: The aim of the present study was to evaluate the possible role of GABAB receptor in responses induced by repeated nicotine administration in Swiss Webster mice. RESULTS: Nicotine hydrogen tartrate salt (0.5 mg/kg, s.c.) administration induced rewarding properties in the conditioning place preference test. The GABAB receptor agonist, baclofen (3 mg/kg, i.p.) abolished the rewarding properties induced by nicotine hydrogen tartrate salt (0.5 mg/kg, s.c.). In addition, naloxone-precipitated nicotine withdrawal induced somatic manifestations, anxiety-like effects in the elevated plus maze test and dysphoric manifestations in the conditioned place aversion paradigm. Baclofen (2 and 3 mg/kg, i.p.) prevented the somatic manifestations and the anxiety-like effects associated with naloxone-precipitated nicotine withdrawal but not the dysphoric manifestations. CONCLUSIONS: These results showed that nicotine rewarding properties and negative aspects of nicotine withdrawal, such as anxiety-like effects and somatic manifestations, can be modulated by the GABAB receptor activity. This study now reveals a novel possible application of baclofen to develop new therapeutic strategies to achieve smoking cessation. PMID: 24553576 [PubMed - as supplied by publisher]